NeuBase Therapeutics Overview
- Year Founded
-
2009
- Status
-
Out of Business
- Employees
-
37
- Latest Deal Type
-
Out of Business
NeuBase Therapeutics General Information
Description
Developer of a modular antisense technology platform intended to address any rare genetic diseases. The company offers research and development of antisense-based drugs targeting genetic diseases such as huntington's disease, myotonic dystrophy, and certain cancers.
Contact Information
Website
www.neubasetherapeutics.comCorporate Office
- 350 Technology Drive
- Suite 421
- Pittsburgh, PA 15219
- United States
Corporate Office
- 350 Technology Drive
- Suite 421
- Pittsburgh, PA 15219
- United States
NeuBase Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Out of Business | 03-Jan-2025 | Completed | Out of Business | |||
| 6. Secondary Transaction - Open Market | 06-Sep-2023 | Completed | Generating Revenue | |||
| 5. PIPE | 30-Jun-2023 | Completed | Generating Revenue | |||
| 4. 2PO | 29-Apr-2020 | Completed | Generating Revenue | |||
| 3. Reverse Merger | 15-Jul-2019 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 01-Jul-2019 | $9M | $9M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Startup |
NeuBase Therapeutics Comparisons
Industry
Financing
Details
NeuBase Therapeutics Competitors (3)
One of NeuBase Therapeutics’s 3 competitors is Histogen, a Formerly VC-backed company based in San Ramon, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Histogen | Formerly VC-backed | San Ramon, CA | ||||
| 0913693 BC | Corporation | Vancouver, Canada | ||||
| Decoy Therapeutics | Formerly VC-backed | Houston, TX |
NeuBase Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NeuBase Therapeutics Patents
NeuBase Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250360158-A1 | Oligonucleotide analogue formulations | Pending | 13-Jun-2022 | ||
| WO-2023244536-A2 | Oligonucleotide analogue formulations | Inactive | 13-Jun-2022 | ||
| WO-2023244536-A3 | Oligonucleotide analogue formulations | Inactive | 13-Jun-2022 | ||
| WO-2023039068-A1 | Compositions and methods for synthesis of peptide nucleic acid intermediates | Inactive | 08-Sep-2021 | ||
| WO-2023039062-A1 | Peptide nucleic acids comprising 2-aminopyridine and related methods of use thereof | Inactive | 08-Sep-2021 | A61P7/06 |
NeuBase Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NeuBase Therapeutics Investments & Acquisitions (3)
NeuBase Therapeutics’s most recent deal was a Corporate Asset Purchase with Vera Therapeutics (Gene Modulation Technology) for . The deal was made on 20-Apr-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vera Therapeutics (Gene Modulation Technology) | 20-Apr-2021 | Corporate Asset Purchase | Buildings and Property | ||
| Ohr Pharmaceutical | 12-Jul-2019 | Merger/Acquisition | Pharmaceuticals | ||
| DepYmed | 01-Jan-2014 | Joint Venture | Drug Discovery |
NeuBase Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
NeuBase Therapeutics FAQs
-
When was NeuBase Therapeutics founded?
NeuBase Therapeutics was founded in 2009.
-
Where is NeuBase Therapeutics headquartered?
NeuBase Therapeutics is headquartered in Pittsburgh, PA.
-
What is the size of NeuBase Therapeutics?
NeuBase Therapeutics has 37 total employees.
-
What industry is NeuBase Therapeutics in?
NeuBase Therapeutics’s primary industry is Drug Discovery.
-
Is NeuBase Therapeutics a private or public company?
NeuBase Therapeutics is a Private company.
-
What is NeuBase Therapeutics’s current revenue?
The current revenue for NeuBase Therapeutics is .
-
How much funding has NeuBase Therapeutics raised over time?
NeuBase Therapeutics has raised $50.2M.
-
Who are NeuBase Therapeutics’s competitors?
Histogen, 0913693 BC, and Decoy Therapeutics are competitors of NeuBase Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
